Table 3.
Treatment-emergent adverse events.
| Treatment-emergent adverse event, N (%) | Dose |
||||
|---|---|---|---|---|---|
| Placebo |
50 mg |
100 mg |
200 mg |
400 mg |
|
| (N = 19/86; 22%) | (N = 53/82; 65%) | (N = 59/82; 72%) | (N = 61/71; 86%) | (N = 59/70; 84%) | |
| Sensation of heaviness | 1 (1.2) | 4 (4.9) | 4 (4.9) | 7 (9.9) | 5 (7.1) |
| Nausea | 0 (0.0) | 4 (4.9) | 8 (9.8) | 2 (2.8) | 5 (7.1) |
| Paresthesia | 2 (2.3) | 2 (2.4) | 9 (11.0) | 12 (16.9) | 14 (20.0) |
| Somnolence | 2 (2.3) | 8 (9.8) | 10 (12.2) | 8 (11.3) | 8 (11.4) |
| Vertigo | 1 (1.2) | 8 (9.8) | 12 (14.6) | 12 (16.9) | 16 (22.9) |
| Fatigue | 2 (2.3) | 10 (12.2) | 17 (20.7) | 15 (21.1) | 16 (22.9) |
| Dizziness | 0 (0.0) | 19 (23.2) | 21 (25.6) | 27 (38.0) | 26 (37.1) |